Shares of Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) have earned a consensus recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $76.6667.
HSIC has been the subject of several analyst reports. Wall Street Zen cut shares of Henry Schein from a "buy" rating to a "hold" rating in a research note on Saturday. Robert W. Baird reiterated a "neutral" rating and issued a $72.00 target price (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Barrington Research reiterated an "outperform" rating and issued a $78.00 target price on shares of Henry Schein in a research note on Tuesday, September 23rd. Stifel Nicolaus reiterated a "hold" rating and issued a $75.00 target price (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Finally, UBS Group decreased their target price on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating for the company in a research note on Wednesday, August 6th.
View Our Latest Report on Henry Schein
Henry Schein Stock Performance
Shares of NASDAQ HSIC opened at $63.17 on Monday. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51. Henry Schein has a 12 month low of $60.56 and a 12 month high of $82.49. The company has a 50 day simple moving average of $67.48 and a two-hundred day simple moving average of $68.80. The stock has a market cap of $7.66 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 2.08 and a beta of 0.81.
Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the previous year, the firm posted $1.23 earnings per share. The business's revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, analysts predict that Henry Schein will post 4.74 earnings per share for the current year.
Institutional Investors Weigh In On Henry Schein
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Artisan Partners Limited Partnership increased its holdings in Henry Schein by 0.9% in the 2nd quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company's stock worth $472,064,000 after acquiring an additional 55,653 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Henry Schein by 6.5% in the 1st quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company's stock worth $436,489,000 after acquiring an additional 390,399 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company's stock worth $165,594,000 after acquiring an additional 2,199,695 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Henry Schein by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,240,933 shares of the company's stock worth $153,480,000 after acquiring an additional 103,384 shares in the last quarter. Finally, Burgundy Asset Management Ltd. increased its holdings in Henry Schein by 33.9% in the 1st quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company's stock worth $153,105,000 after acquiring an additional 566,530 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.
About Henry Schein
(
Get Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.